The objectives of this intermediate-size expanded access protocol are to assess the safety and efficacy of remestemcel-L in participants with MIS-C associated with COVID-19.
Full Title of Study: “Intermediate-size Expanded Access of Remestemcel-L, Human Mesenchymal Stromal Cells, for Multisystem Inflammatory Syndrome in Children (MIS-C) Associated With Coronavirus Disease (COVID-19)”
- Study Type: Expanded Access
This intermediate-size expanded access protocol plans to treat approximately 50 children or adolescents, male and female, with MIS-C associated with COVID-19. Participants who are 2 months to 17 years of age, inclusive, will be enrolled at multiple clinical sites across the United States.
- Biological: Remestemcel-L
- Participants may receive up to 2 infusions of 2 x 10^6 remestemcel-L within a 5-day period.
- Drug: Hydrocortisone
- Participants who are not currently taking a corticosteroid will receive hydrocortisone, 0.5-1 milligram per kilogram (mg/kg), up to 50 mg IV, at least 30 minutes prior to the infusion of remestemcel-L.
- Drug: Diphenhydramine
- Participants will receive diphenhydramine, 0.5-1 mg/kg, up to 50 mg IV, at least 30 minutes prior to the infusion of remestemcel-L.
Participating in This Clinical Trial
Inclusion Criteria 1. 2 months to 17 years of age, inclusive 2. Positive for current or recent SARS-CoV-2 (COVID-19) infection by real-time reverse transcription polymerase chain reaction (RT-PCR), serology, or antigen test; or COVID-19 exposure within the 4 weeks prior to the onset of symptoms AND no alternative plausible diagnoses 3. Presenting with:
Gender Eligibility: All
Minimum Age: 2 Months
Maximum Age: 17 Years
- Lead Sponsor
- Mesoblast International Sàrl
- Provider of Information About this Clinical Study
- Overall Official(s)
- Kenneth M. Borow, MD, Study Director, Mesoblast, Inc.
- Overall Contact(s)
- Elizabeth Burke, ANP-C, 646-315-1725, email@example.com
Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.